Delving into the Latest Updates on Sorbonne Paris Cité with Synapse

概览

疾病领域	数量

内分泌与代谢疾病	1

排名前五的药物类型	数量

激素	1

关联

1

项与 Sorbonne Paris Cité 相关的药物

Insulin analogs(Sorbonne Paris Cité)

靶点-

作用机制-

在研机构

Sorbonne Paris Cité

原研机构

Sorbonne Paris Cité

在研适应症

2型糖尿病

非在研适应症-

最高研发阶段临床阶段不明

首次获批国家/地区-

首次获批日期-

1

项与 Sorbonne Paris Cité 相关的临床试验

ISRCTN84373661 / CompletedN/A

Genealogy and quality of life in patient with keratoconus: a cross-sectional cohort study

开始日期2015-01-01

申办/合作机构

Sorbonne Paris Cité

[+1]

100 项与 Sorbonne Paris Cité 相关的临床结果

登录后查看更多信息

0 项与 Sorbonne Paris Cité 相关的专利（医药）

登录后查看更多信息

186

项与 Sorbonne Paris Cité 相关的文献（医药）

2020-11-01·Nature Reviews Cancer1区 · 医学

The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy

1区 · 医学

Review

作者: Galon, Jérôme ; Bruni, Daniela ; Angell, Helen K

The international American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) tumour-node-metastasis (TNM) staging system provides the current guidelines for the classification of cancer. However, among patients within the same stage, the clinical outcome can be very different. More recently, a novel definition of cancer has emerged, implicating at all stages a complex and dynamic interaction between tumour cells and the immune system. This has enabled the definition of the immune contexture, representing the pre-existing immune parameters associated with patient survival. Even so, the role of distinct immune cell types in modulating cancer progression is increasingly emerging. An immune-based assay named the 'Immunoscore' was defined to quantify the in situ T cell infiltrate and was demonstrated to be superior to the AJCC/UICC TNM classification for patients with colorectal cancer. This Review provides a broad overview of the main immune parameters positively or negatively shaping cancer development, including the Immunoscore, and their prognostic and predictive value. The importance of the immune system in cancer control is demonstrated by the requirement for a pre-existing intratumour adaptive immune response for effective immunotherapies, such as checkpoint inhibitors. Finally, we discuss how the combination of multiple immune parameters, rather than individual ones, might increase prognostic and/or predictive power.

2019-06-01·Environmental and Molecular Mutagenesis

Risk of cancer in children exposed to antiretroviral nucleoside analogues in utero: The french experience

Article

作者: Clavel, Jacqueline ; Faye, Albert ; Mandelbrot, Laurent ; Hleyhel, Mira ; Sibiude, Jeanne ; Blanche, Stéphane ; Goujon, Stéphanie ; Dollfus, Catherine ; Tubiana, Roland ; Warszawski, Josiane

All nucleoside analogues for treating HIV infection, due to their capacity to integrate into and alter human DNA, are experimentally genotoxic to some extent. The long‐term oncogenic risk after in utero exposure remains to be determined. Cancer incidence in uninfected children exposed to nucleos(t)ide reverse transcriptase inhibitors (NRTIs) was evaluated, by cross‐checking against the National Cancer Registry, in the French perinatal study of children born to HIV+ mothers. Twenty‐one cancers were identified in 15,163 children (median age: 9.9 years [interquartile range (IQR): 5.8–14.2]) exposed to at least one NRTI in utero between 1990 and 2014. Five of these children were exposed to zidovudine monotherapy, and 15 to various combinations, seven of which included didanosine. Overall, the total number of cases was not significantly different from that expected for the general population (SIR = 0.8[0.47–1.24]), but the number of cases after didanosine exposure was twice that expected (SIR = 2.5 [1.01–5.19]). Didanosine accounted for only 10% of prescriptions but was associated with one‐third of cancers. In multivariate analysis, didanosine exposure was significantly associated with higher risk (HR = 3.0 [0.9–9.8]). This risk was specifically linked to first‐trimester exposure (HR = 5.5 [2.1–14.4]). Three cases of pineoblastoma, a very rare cancer, were observed, whereas 0.03 were expected. Two were associated with didanosine exposure. Despite reassuring data overall, there is strong evidence to suggest that didanosine displays transplacental oncogenicity. These findings cannot be extrapolated to other NRTIs, but they highlight the need for comprehensive evaluations of the transplacental genotoxicity of this antiretroviral class. Environ. Mol. Mutagen., 60:404–409, 2019. © 2017 Wiley Periodicals, Inc.

2015-05-04·OncoImmunology2区 · 医学

Trial watch: Naked and vectored DNA-based anticancer vaccines

2区 · 医学

ArticleOA

作者: Kroemer, Guido ; Fucikova, Jitka ; Eggermont, Alexander ; Cremer, Isabelle ; Sautès-Fridman, Catherine ; Spisek, Radek ; Castoldi, Francesca ; Tartour, Eric ; Bloy, Norma ; Galluzzi, Lorenzo ; Zitvogel, Laurence ; Aranda, Fernando ; Buqué, Aitziber ; Galon, Jérôme

One type of anticancer vaccine relies on the administration of DNA constructs encoding one or multiple tumor-associated antigens (TAAs). The ultimate objective of these preparations, which can be naked or vectored by non-pathogenic viruses, bacteria or yeast cells, is to drive the synthesis of TAAs in the context of an immunostimulatory milieu, resulting in the (re-)elicitation of a tumor-targeting immune response. In spite of encouraging preclinical results, the clinical efficacy of DNA-based vaccines employed as standalone immunotherapeutic interventions in cancer patients appears to be limited. Thus, efforts are currently being devoted to the development of combinatorial regimens that allow DNA-based anticancer vaccines to elicit clinically relevant immune responses. Here, we discuss recent advances in the preclinical and clinical development of this therapeutic paradigm.

100 项与 Sorbonne Paris Cité 相关的药物交易

登录后查看更多信息

100 项与 Sorbonne Paris Cité 相关的转化医学

登录后查看更多信息